AUSTIN, Texas, Feb 23, 2021 (SEND2PRESS NEWSWIRE) Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.
The HEPtune platform, which utilizes heparosan, a naturally occurring polysaccharide, has been validated as a novel half-life extension and drug delivery alternative to commonly used polyethylene glycol (PEG). Unlike PEG, heparosan is naturally found in humans, is completely biodegradable, and will not trigger anaphylactic shock or anti-drug antibodies. The HEPtune platform has been applied to numerous drug classes including biologics, and small molecules via nanocarriers, including liposomes.
Caisson Biotech and Heparinex Announce Positive Exam Report of European Patent and the Discovery of a New Class of Sugar Polymers
enewschannels.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from enewschannels.com Daily Mail and Mail on Sunday newspapers.
Caisson Biotech, LLC and Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of Sugar Polymers
floridanewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from floridanewswire.com Daily Mail and Mail on Sunday newspapers.
AUSTIN, Texas, Feb 04, 2021 (SEND2PRESS NEWSWIRE) Pure Protein, LLC (Pure Protein) and subsidiary company Pure Transplant Solutions, LLC (PTS), announced today that Blake Harlan has been promoted to President and Rico Buchli, PhD to Vice President of Products and Services.
In his new role, Mr. Harlan will be responsible for leading Pure Protein’s new product line commercialization while ensuring sustainable profitability and growth. He will also oversee the implementation and launch of Pure Transplant Solutions clinical diagnostics and transplant monitoring programs.
Going forward, Dr. Buchli will now be responsible for overseeing the products and services offered through HLAProtein.com in addition to expanding the portfolio of the companies’ offerings. Furthermore, he will have the scientific oversight for the completion and launch of Pure Transplant Solutions’ diagnostic products and monitoring programs.